Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Blood and Urine-Based Liquid Biopsy for early stage cancer investigation: Taken Clear Renal Cell Carcinoma as A Model

ABSTRACT: We analyzed samples of tumor tissue, plasma, and urine from a cohort of 27 ccRCC patients with T1-2 stage and 27 matched healthy controls, using liquid chromatography–mass spectrometry (LC-MS) for proteomic analysis. We integrated the differential proteins found in the three types of samples to explore ccRCC-associated molecular changes.

ORGANISM(S): Homo Sapiens

SUBMITTER: Wei Sun

PROVIDER: PXD043118 | iProX | Tue Jun 20 00:00:00 BST 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Blood- and Urine-Based Liquid Biopsy for Early-Stage Cancer Investigation: Taken Clear Renal Cell Carcinoma as a Model.

Liu Xiaoyan X Zhang Mingxin M Shao Chen C Sun Haidan H Zhang Binbin B Guo Zhengguang Z Sun Jiameng J Qi Feng F Zhang Yushi Y Niu Haitao H Sun Wei W

Molecular & cellular proteomics : MCP 20230620 8

Liquid biopsy is a noninvasive technique that can provide valuable information for disease characterization by using biofluids as a source of biomarkers. Proteins found in biofluids can offer a wealth of information for understanding pathological processes. In this study, we used early-stage clear cell renal cell carcinoma (ccRCC) as a model to explore the proteomic relationships among tissue, plasma, and urine. We analyzed samples of tumor tissue, plasma, and urine from a cohort of 27 ccRCC pat ...[more]

PMID: 37348606

Similar Datasets

Clear cell renal cell carcinoma (ccRCC) samples

Project description:To select signatures of ccRCC, 265 ccRCC samples were obtained from the Van Andel Research Institute. Gene expression profiles of 265 samples were determined using the HG-U133_Plus_2 platform.

2017-08-08 | GSE73731 | GEO

Blood- and Urine-Based Liquid Biopsy for Early-Stage Cancer Investigation: Taken Clear Renal Cell Carcinoma as a Model.

Project description:Liquid biopsy is a noninvasive technique that can provide valuable information for disease characterization by using biofluids as a source of biomarkers. Proteins found in biofluids can offer a wealth of information for understanding pathological processes. In this study, we used early-stage clear cell renal cell carcinoma (ccRCC) as a model to explore the proteomic relationships among tissue, plasma, and urine. We analyzed samples of tumor tissue, plasma, and urine from a cohort of 27 ccRCC patients with T1-2 stage and 27 matched healthy controls, using liquid chromatography-mass spectrometry (LC-MS) for proteomic analysis. We integrated the differential proteins found in the three types of samples to explore ccRCC-associated molecular changes. Our results showed that both plasma and urine proteomes could reflect functional changes in tumor tissue. In plasma, cytoskeletal proteins and metabolic enzymes were differentially expressed, while in urine, adhesion molecules and defense proteins showed differential levels. The differential proteins found in plasma and urine both reflect the binding and catalytic activity of tumor tissue. Additionally, proteins only changed in biofluids could reflect body immune response changes, with plasma proteins involved in actin cytoskeleton and oxidative stress, and urine proteins involved in granulocyte adhesion and leukocyte extravasation signaling. Plasma and urine proteins could effectively distinguish RCC from control, with good performances (plasma/urine: 92.6%/92.6% specificity, 96.3%/92.6% sensitivity, and an area under the curve of 0.981/0.97). In conclusion, biofluids could not only reflect functional changes in tumor tissue but also reflect changes in the body's immune response. These findings will benefit the understanding of body biomarkers in tumors and the discovery of potential disease biomarkers.

| S-EPMC10416070 | biostudies-literature

microRNA Profile in Stage I Clear Cell Renal Cell Carcinoma Predicts Progression to Metastatic Disease [screen]

Project description:To identify microRNA (miRNA) profiles of small, pathologically confirmed stage 1 clear cell renal cell carcinoma (ccRCC) tumors that could predict progression to metachronous metastatic disease. : Fifty-five pathologic stage 1 ccRCC tumors ≤5cm from two institutions were examined in an initial miRNA screening, followed by a validation study. This investigation identified miRNA biomarkers that may differentiate between non-progressive ccRCC tumors and those that progress to metastatic disease in this group of stage I tumors. The data presented in this workbook are for the 20 samples analyzed in the screening analysis. The data were normalized to the global mean of all targets with a Cq<35. Prior to normalization each value was scaled by the corresponding internal plate calibrator value.

2020-06-01 | GSE131959 | GEO

MicroRNA expression of clear cell papillary renal cell carcinoma

Project description:to see if CCPRCC has a distinct miRNA profile from CCRCC and PRCC miRNA v.2.0 chips on two portions of five CCPRCC cases (total 10 samples), three portions of two CCRCC cases and a further three CCRCC cases (total 9 samples), and five type I PRCC samples; a total of 24 samples

2013-10-23 | E-GEOD-51554 | biostudies-arrayexpress

Clear Cell Renal Cell Carcinoma Serum and Tissue Proteomics

Project description:LC-MS/MS analysis was performed on tissue and serum samples from ten PDX mice derived from ccRCC tissues obtained through nephrectomy, autopsy, or biopsy, as well as six control non-PDX serum samples, and 32 normal human kidney samples. All data was collected in triplicate.

2025-05-07 | PXD061075 | Pride

Proteomics characterization of clear cell renal cell carcinoma

Project description:The aims of the study was to explore the tumor proteome of patients diagnosed with localized ccRCC and treated with surgery and the identification of altered pathways that could be the target of new treatments. A total of 165 FFPE tumor samples from patients diagnosed with ccRCC were analyzed using DIA-proteomics. Proteomics ccRCC subtypes were defined using a Consensus Cluster Algorithm (CCA) and characterized by a functional approach using probabilistic graphical models and survival analyses. Two proteomics subtypes of ccRCC (CCA1 and CCA2) were identified by CCA using the high confidence proteins only. Characterization of molecular differences between CCA1 and CCA2 was performed in two steps. First, we defined 514 proteins showing differential expression between the two subtypes using a significance analysis of microarrays analysis. Proteins overexpressed in CCA1 were mainly related to translation and ribosome, while proteins overexpressed in CCA2 were mainly related to focal adhesion and membrane. Second, a functional analysis using probabilistic graphical models was performed. The CCA1 subtype is characterized by an increased expression of proteins related to glycolysis, mitochondria, translation, adhesion proteins related to cytoskeleton and actin, nucleosome, and spliceosome, while CCA2 subtype showed higher expression o proteins involved in focal adhesion, extracellular matrix and collagen organization.

2025-05-09 | PXD039258 | Pride

microRNA Profile in Stage I Clear Cell Renal Cell Carcinoma Predicts Progression to Metastatic Disease [validation]

Project description:To identify microRNA (miRNA) profiles of small, pathologically confirmed stage 1 clear cell renal cell carcinoma (ccRCC) tumors that could predict progression to metachronous metastatic disease. : Fifty-five pathologic stage 1 ccRCC tumors ≤5cm from two institutions were examined in an initial miRNA screening, followed by a validation study. This investigation identified miRNA biomarkers that may differentiate between non-progressive ccRCC tumors and those that progress to metastatic disease in this group of stage I tumors. The data presented in this workbook are for the samples analyzed in the custom array analysis. The data were normalized to the average of the insignificant control miRNA: miRs-28-5p, -125-5p, and -191-5p, selected from the screening array dataset using NormFinder©. Prior to normalization each value was scaled by the corresponding internal plate calibrator value (see below).

2020-06-01 | GSE131960 | GEO

Identification of metastasis associated genes in clear cell renal cell carcinoma

2013-05-25 | GSE47352 | GEO

Proteotranscriptomic analysis reveals stage specific changes in the molecular landscape of clear-cell renal cell carcinoma

Project description:Label-free proteomics data matched tumor and normal-adjacent tissues from 84 patients with stage I to IV ccRCC, by using pooled samples.

2016-02-12 | MSV000079511 | MassIVE

Identification of metastasis associated genes in clear cell renal cell carcinoma

Project description:This study investigates the genes that promote clear cell renal cell carcimoma (ccRCC) metastasis using 4 primary metastatic and 5 non-metastatic tumor samples. U133 plus 2.0 array was used to identify the diffrently expressed genes between the primary metastatic and non metastatic ccRCC samples To identify differences in gene expression assoctiated with ccRCC metastasis, 4 primary metastatic and 5 non-metastatic ccRCC samples were used to perform expression profiling.

2013-05-25 | E-GEOD-47352 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data